Sai Parenterals Ltd (SAIPARENT) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Sai Parenteral’s was incorporated on January 12, 2001. The company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. It is in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (CDMO) products and services for the domestic and international markets. Its portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. 

In the injectables segment, the company has capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampoules, and vials. Branded Generic Formulations are those off-patent pharmaceutical products that are produced and sold by the company under its own brand names. It manufactures and sells Branded Generic Formulations to a diverse customer base, including central and state government agencies, pharmaceutical companies, public and private hospitals and super stockists in the domestic market.

The company’s CDMO business includes product development, which involves designing and developing new pharmaceutical products, validation batches i.e. trial runs conducted to ensure consistent manufacturing quality, stability studies, which assess drug performance under various conditions, dossier compilation, which involves preparing and compiling documents required for product approvals, international regulatory filings which involves submission to regulatory authorities in a particular jurisdiction to register or sell a drug/medicine and commercial manufacturing.

Business area of the company 

The company, along with its subsidiaries, carries out contract research and manufacturing activities for customers engaged in pharmaceutical industries.

Business verticals of the company

• Branded Generic Formulations - The company’s Branded Generic Formulations business includes (i) Domestic Branded Generic Formulations, and (ii) Export Branded Generic Formulations, marketed under our own brand name through central and state government agencies, pharmaceutical companies, public and private hospitals and super stockists in the domestic market.
• CDMO products & services - The company’s offers end-to-end CDMO products & services, providing comprehensive support for developing new products from development and testing to obtaining regulatory approvals and large-scale manufacturing product. 

Awards, accreditations and recognition 

• 2025: Healthcare Iconic Fashion and Awards (HIFAA) Award in the category of Best Emerging Company.

History and milestones

• 2001: The company was incorporated as a Private Limited Company under the name of Sai Parenteral’s Private Limited.
• 2016: Change in the ownership of the company, due to acquisition of Equity Shares by the Promoters from the erstwhile promoters of the company.
• 2016: Acquired Unit-I and Unit-II.
• 2021: Launch of Prefilled technology equipment in Unit-I.
• 2022: Acquired Unit III and related business from Reichindia Pharma Limited. 
• 2022:  Acquired Unit IV and related business from Medreich Limited. 
• 2023: Incorporated, SP Analytics Private Limited one of the subsidiary.
• 2023: The company achieved a turnover of Rs 1,000 million.
• 2024: The company acquired 100% shareholding of Revat Laboratories Private Limited, pursuant to which it became a wholly owned subsidiary of the company.
• 2025: Incorporated a wholly owned subsidiary, Sai Parenterals Pte. Limited in Singapore. 
• 2025: Acquisition of foreign step-down subsidiaries, Noumed Pharmaceuticals Pty Limited in Australia and Noumed Pharmaceuticals Limited in New Zeala.